Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum

详细信息    查看全文

• 作者：David S. Knopman^a ; ^b ; ^{knopman@mayo.edu" class="auth_mail" title="E-mail the corresponding author} ; Clifford R. Jack Jr.^b ; ^c ; Emily S. Lundt^d ; Stephen D. Weigand^d ; Prashanthi Vemuri^b ; ^c ; Val J. Lowe^b ; ^c ; Kejal Kantarci^b ; ^c ; Jeffrey L. Gunter^c ; ^e ; Matthew L. Senjem^c ; ^e ; Michelle M. Mielke^a ; ^f ; Mary M. Machulda^b ; ^g ; Rosebud O. Roberts^a ; ^f ; Bradley F. Boeve^a ; ^b ; David T. Jones^a ; ^b ; ^c ; Ronald C. Petersen^a ; ^b ; ^f
• 关键词：Alzheimer's disease ; MR imaging ; FDG PET imaging ; PIB PET imaging ; Longitudinal study
• 刊名：Neurobiology of Aging
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：46
• 期：Complete
• 页码：32-42
• 全文大小：1785 K

文摘

The availability of antemortem biomarkers for Alzheimer's disease (AD) enables monitoring the evolution of neurodegenerative processes in real time. Pittsburgh compound B (PIB) positron emission tomography (PET) was used to select participants in the Mayo Clinic Study of Aging and the Mayo Alzheimer's Disease Research Center with elevated β-amyloid, designated as “A+,” and hippocampal volume and ¹⁸fluorodeoxyglucose (FDG) positron emission tomography were used to characterize participants as having evidence of neurodegeneration (“N+”) at the baseline evaluation. There were 145 clinically normal (CN) A+ individuals, 62 persons with mild cognitive impairment (MCI) who were A+ and 20 with A+ AD dementia. Over a period of 1–6 years, MCI A+N+ individuals showed declines in medial temporal, lateral temporal, lateral parietal, and to a lesser extent, medial parietal regions for both FDG standardized uptake value ratio and gray matter volume that exceeded declines seen in the CN A+N+ group. The AD dementia group showed declines in the same regions on FDG standardized uptake value ratio and gray matter volume with rates that exceeded that in MCI A+N+. Expansion of regional involvement and faster rate of neurodegeneration characterizes progression in the AD pathway.